Composite versus individual biomarkers for predicting clinical benefit to PD-1 blockade in NSCLC 95 3 Table 2. Patient characteristics and treatment outcomes for training and validation cohorts. Training cohort Validation cohort P-value n=55 n=80 Sex P=1.00 Male, no.(%) 30 (55%) 44 (55%) Female, no.(%) 25 (45%) 36 (45%) Age (years), mean (SD) P=0.20 62 (10.1) 65 (7.5) Smoking (never/ex/current) P=0.64 5/44/6 12/51/17 Pack years, median (IQR) P=0.90 29 (20) 30 (28) PS, no. (%) P=0.46 0 16 (29%) 16 (20%) 1 29 (53%) 50 (62%) ≥2 10 (18%) 14 (18%) Pathology, no.(%) P=0.19 Adeno 35 (64%) 50 (62%) Squamous 10 (18%) 20 (25%) LCNEC, NSCLC-type 0 (0%) 3 (4%) NSCLC, NOS 10 (18%) 7 (9%) Mutations, no. (%) P=0.86 KRAS positive 19 (35%) 30 (38%) PD-L1 TPS, no. (%) Negative <1% P=1.00 30 (55%) 43 (54%) Positive ≥1% 25 (45%) 36 (45%) Negative <50% P=0.66 43 (78%) 65 (81%) Positive ≥50% 12 (22%) 14 (18%) Unknown 0 (0%) 1 (1%) Brain metastases, no. (%) P=0.67 13 (24%) 16 (20%) Line of treatment, no.(%) P=0.63 1 0 (0%) 1 (1%) 2 42 (76%) 56 (70%) >2 13 (24%) 23 (29%) Best Overall Response P=0.62 CR/PR 11 (20%) 15 (19%) SD 5 (9%) 16 (20%) SD (PFS <6 months) 0 (0%) 6 (7%) SD (PFS ≥6 months) 5 (9%) 10 (13%) PD 39 (71%) 49 (61%) DC at 6 months P=0.85 16 (29%) 25 (31%) at 12 months P=0.83 12 (22%) 16 (20%)
RkJQdWJsaXNoZXIy MTk4NDMw